BACKGROUND: Esophageal cancer often involves direct invasion of adjacent organs and patient survival rates are low. Sarcopenia has been reported to be associated with a poor prognosis in several types of malignancies. However, the impact of sarcopenia on the long-term survival of patients with unresectable locally advanced esophageal cancer remains unclear. PATIENTS AND METHODS: A total of 48 patients undergoing definitive chemoradiotherapy at our Institution from October 2012 to December 2015 were enrolled; their data were compared according to patient skeletal muscle index (SMI): low SMI (sarcopenia group), n=34; normal SMI (non-sarcopenia group), n=14. RESULTS: There were no significant differences in the incidence of severe adverse events and dose reduction rate between the two groups. The incidence of nutritional support was significantly higher in the groups with sarcopenia than in the non-sarcopenia group (44.1% vs. 7.1%, p=0.077). Response rates were significantly lower in the sarcopenia group than in the non-sarcopenia group (43.8% vs. 78.6%, p=0.025). The overall survival rate in the group with sarcopenia was significantly lower than that in the non-sarcopenia group (3-year: 36.95% vs. 63.9%, p=0.018). CONCLUSION: Sarcopenia prior to treatment may worsen the long-term survival of patients with unresectable locally advanced esophageal cancer. Further well-designed prospective trials are needed to estimate whether adequate nutritional support has a favorable impact on therapeutic outcomes in this population. Copyright
BACKGROUND:Esophageal cancer often involves direct invasion of adjacent organs and patient survival rates are low. Sarcopenia has been reported to be associated with a poor prognosis in several types of malignancies. However, the impact of sarcopenia on the long-term survival of patients with unresectable locally advanced esophageal cancer remains unclear. PATIENTS AND METHODS: A total of 48 patients undergoing definitive chemoradiotherapy at our Institution from October 2012 to December 2015 were enrolled; their data were compared according to patient skeletal muscle index (SMI): low SMI (sarcopenia group), n=34; normal SMI (non-sarcopenia group), n=14. RESULTS: There were no significant differences in the incidence of severe adverse events and dose reduction rate between the two groups. The incidence of nutritional support was significantly higher in the groups with sarcopenia than in the non-sarcopenia group (44.1% vs. 7.1%, p=0.077). Response rates were significantly lower in the sarcopenia group than in the non-sarcopenia group (43.8% vs. 78.6%, p=0.025). The overall survival rate in the group with sarcopenia was significantly lower than that in the non-sarcopenia group (3-year: 36.95% vs. 63.9%, p=0.018). CONCLUSION:Sarcopenia prior to treatment may worsen the long-term survival of patients with unresectable locally advanced esophageal cancer. Further well-designed prospective trials are needed to estimate whether adequate nutritional support has a favorable impact on therapeutic outcomes in this population. Copyright
Authors: K Harada; S Ida; Y Baba; T Ishimoto; K Kosumi; R Tokunaga; D Izumi; M Ohuchi; K Nakamura; Y Kiyozumi; Y Imamura; M Iwatsuki; S Iwagami; Y Miyamoto; Y Sakamoto; N Yoshida; M Watanabe; H Baba Journal: Dis Esophagus Date: 2015-06-30 Impact factor: 3.429
Authors: M Paireder; R Asari; I Kristo; E Rieder; D Tamandl; A Ba-Ssalamah; S F Schoppmann Journal: Eur J Surg Oncol Date: 2016-12-14 Impact factor: 4.424
Authors: Connie Yip; Vicky Goh; Andrew Davies; James Gossage; Rosalind Mitchell-Hay; Orla Hynes; Nick Maisey; Paul Ross; Andrew Gaya; David B Landau; Gary J Cook; Nyree Griffin; Robert Mason Journal: Eur Radiol Date: 2014-02-18 Impact factor: 5.315
Authors: Lucas Stone; Brennan Olson; Alia Mowery; Stephanie Krasnow; Angie Jiang; Ryan Li; Joshua Schindler; Mark K Wax; Peter Andersen; Daniel Marks; Virginie Achim; Daniel Clayburgh Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-07-01 Impact factor: 6.223
Authors: Camila T B Gabiatti; Mariane C L Martins; Daniela L Miyazaki; Leandro P Silva; Fabiana Lascala; Ligia T Macedo; Maria Carolina Santos Mendes; José Barreto Campello Carvalheira Journal: Cancer Med Date: 2019-10-01 Impact factor: 4.452
Authors: Namrata S Chauhan; Stephen Rajan Samuel; Niranjan Meenar; Pu Prakash Saxena; Justin W L Keogh Journal: PeerJ Date: 2020-02-26 Impact factor: 2.984